8-K: PharmaCyte Biotech Faces Nasdaq Delisting Warning

PharmaCyte Biotech, Inc. received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, initiating a 180-day compliance period.

Summary

• PharmaCyte Biotech, Inc. (PMCB) received a notice from Nasdaq on December 1, 2025, indicating non-compliance with the minimum bid price requirement.
• The Nasdaq Listing Rule 5550(a)(2) requires a minimum bid price of $1.00 per share.
• The company's common stock closed below $1.00 for 30 consecutive business days preceding the notice.
• There is no immediate effect on the listing or trading of PMCB common stock.
• The company has 180 calendar days, until June 1, 2026, to regain compliance.
• Compliance can be regained if the closing bid price is at least $1.00 per share for a minimum of 10 consecutive business days.
• If compliance is not met, the company may be eligible for an additional 180-day period, potentially involving a reverse stock split.
• Failure to regain compliance could lead to delisting, with the company retaining the right to appeal.

Sentiment

Score: 3

Explanation: The filing indicates a significant negative event (Nasdaq non-compliance notice) which poses a risk of delisting and requires corrective action, potentially a reverse stock split, which can be dilutive or negatively perceived by investors. While there's a compliance period, the underlying issue of low stock price is concerning.

Negatives

• Received a notice of non-compliance from Nasdaq for failing to meet the minimum bid price requirement of $1.00 per share.
• The company's common stock traded below $1.00 for 30 consecutive business days.
• Risk of delisting from The Nasdaq Capital Market if compliance is not regained.

Risks

• Inability to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
• Potential delisting of common stock from The Nasdaq Capital Market.
• Uncertainty regarding the effectiveness of strategies like a reverse stock split, which also requires stockholder approval.
• No assurance that the company will be able to regain or maintain compliance with Nasdaq's listing requirements.

Future Outlook

The company intends to actively monitor the closing bid price of its common stock and will consider all available options to regain compliance, including a potential reverse stock split, subject to stockholder approval. There is no assurance that compliance will be regained or maintained.

Management Comments

• The Company intends to actively monitor the closing bid price of its common stock and will consider all available options to regain compliance with the Bid Price Rule, including, if appropriate, implementing a reverse stock split, subject to stockholder approval.
• There can be no assurance that the Company will be able to regain or maintain compliance with the Bid Price Rule or the other continued listing requirements of The Nasdaq Capital Market.

Industry Context

This announcement is specific to PharmaCyte Biotech's compliance with Nasdaq listing rules and does not directly reflect broader industry trends. However, maintaining a minimum bid price is a common challenge for smaller biotechnology companies, especially those in development stages, and can impact investor confidence and access to capital markets.

Stakeholder Impact

• Shareholders: Potential for further stock price volatility, risk of delisting from Nasdaq, potential for reverse stock split which can reduce the number of shares held and may not guarantee long-term price stability.
• Investors: Increased uncertainty regarding the company's future listing status and ability to attract capital.

Next Steps

• Actively monitor the closing bid price of common stock.
• Consider all available options to regain compliance with the Bid Price Rule.
• Potentially implement a reverse stock split, subject to stockholder approval.
• If compliance is not regained by June 1, 2026, the company may seek an additional 180-day compliance period.
• Prepare to appeal Nasdaq's determination if delisting notification is received.

Key Dates

Recommendation

The notice of non-compliance with Nasdaq's minimum bid price requirement signals significant underlying issues with the company's valuation and market perception. While there's a compliance period, the risk of delisting is substantial, and potential remedies like a reverse stock split often fail to provide sustained value and can be viewed negatively by the market. The lack of assurance from management regarding regaining compliance further exacerbates the risk, making the stock a high-risk holding with potential for further downside.

Keywords

PharmaCyte Biotech, PMCB, Nasdaq, Delisting Notice, Minimum Bid Price, Compliance, Reverse Stock Split, Biotech, SEC Filing, 8-K